A sizeable minority of patients suffering from major depression do not have their full set of
depressive symptoms relieved by a single medication. Often times, a second medication is
added to a patient's first antidepressant to obtain a better response in hopes of getting the
depressed patient into full remission from symptoms.
A typical psychiatric approach of recent has been to add one of the newer anti-schizophrenia
medications to an existing FDA approved antidepressant in order to achieve better serotonin
levels in the depressed patient's brain. This optimization of brain serotonin helps to
alleviate more depressive symptoms. The newest antipsychotic medication to be FDA approved is
Aripiprazole (Abilify). It may be particularly effective as it may safely elevate sertotonin
through receptor 1a stimulation, receptor 2a blockade. It may also facilitate low levels of
dopamine transmission which is truly novel for this agent when compared to other
schizophrenia drugs. Depressed patients also tend to lack dopamine in their brains. This
makes Aripiprazole and ideal agent to boost both serotonin and dopamine simultaneously. In
theory, this may be an effective way to alleviate more depressive symptoms.
The author suggests to enroll 10 subjects initially in open label fashion to take
Aripiprazole plus their current FDA approved antidepressant to see if further elimination of
depressive symptoms occurs and to show this pharmacological approach as a tolerable
combination of medications. If there are no major safety issues, an amendment to allow 10
additional subjects will be forwarded to provide a better tolerability sample size.
Phase:
Phase 2
Details
Lead Sponsor:
State University of New York - Upstate Medical University